Peptides for sexual health are attracting interest because sexual desire and physical arousal involve more than blood flow alone. The brain, nervous system and reproductive hormones all contribute to sexual response, creating several pathways that researchers can investigate. PT-141 and kisspeptin are two peptides with published human research in this area, although their evidence and medical applications differ considerably.
PT-141, also known as bremelanotide, has progressed from experimental research to an approved prescription medication for a specific female sexual desire disorder in the United States. Kisspeptin remains investigational, with controlled studies exploring its effects on sexual brain activity and arousal in men and women. Understanding those differences helps explain what these peptides may offer—and where the research still has limits.
Libido, Arousal and Erectile Function: What Is the Difference?
Libido means sexual desire: the interest or motivation to engage in sexual activity. Arousal includes the mental and physical responses to sexual stimulation, while erectile function refers specifically to the ability to achieve and maintain an erection. These processes interact, but someone can experience strong desire with difficulty getting an erection, or normal erectile function with little interest in sex.
This distinction matters when evaluating sexual health research. An increase in erectile response does not automatically demonstrate an improvement in libido, and a change in brain activity does not necessarily translate into better sexual experiences outside a laboratory. Researchers studying PT-141 and kisspeptin therefore measure different outcomes, including desire, distress, brain responses and physical arousal.
PT-141: The Best-Known Peptide for Sexual Health
PT-141 is the research name for bremelanotide, a synthetic peptide that activates melanocortin receptors. These receptors are involved in signalling within the nervous system, including pathways associated with sexual response. Its precise mechanism in treating low sexual desire is not fully understood, but it offers a different approach from medications that primarily support penile blood flow.
PT-141 and Female Sexual Desire
In the United States, bremelanotide is approved under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women. “Acquired” means the difficulty developed after a period without that problem, while “generalized” means it occurs across situations, partners or types of stimulation. The condition involves low sexual desire that causes significant distress and is not explained by another medical or psychiatric condition, relationship problems or a medication’s effects.
The two phase 3 RECONNECT trials found that bremelanotide improved measures of sexual desire and reduced distress associated with low desire compared with placebo. However, the trials did not show a significant difference in the number of satisfying sexual events, a secondary outcome. This makes the findings more specific than a broad claim that PT-141 improves every aspect of sexual performance.
PT-141 Research in Men
PT-141 has also been studied in men, including men with erectile dysfunction. An early placebo-controlled study using intranasal PT-141 found significantly greater erectile responses than placebo in healthy participants and men with mild-to-moderate erectile dysfunction. A separate study using subcutaneous administration reported increased erectile responses in men who had an inadequate response to sildenafil, the active ingredient in Viagra.
These studies provide a legitimate basis for discussing PT-141 and male sexual function. However, they were early investigations using specific formulations and controlled conditions, rather than proof of reliable results from commercially sold research vials. Vyleesi’s U.S. approval does not include men, and its label specifically excludes use as a general sexual-performance enhancer.
PT-141 vs Viagra and Cialis
Viagra and Cialis belong to the PDE5 inhibitor class of medications used for erectile dysfunction. They support the blood-flow response involved in an erection by helping preserve signalling that relaxes smooth muscle in the penis. Sexual stimulation is still required, and these medications do not directly function as treatments for low sexual desire.
PT-141 acts through melanocortin signalling rather than PDE5 inhibition, which explains researchers’ interest in its effects on sexual response. However, a different mechanism does not establish that it is stronger, more effective or a suitable replacement for an approved erectile dysfunction treatment. Desire-related difficulties and blood-flow-related difficulties require different considerations.
Kisspeptin and Sexual Desire
Kisspeptin is a naturally occurring peptide involved in reproductive hormone signalling. It helps activate the pathway controlling gonadotropin-releasing hormone, which influences luteinizing hormone and follicle-stimulating hormone. Researchers have also investigated its effects on brain networks involved in sexual and emotional processing, expanding interest beyond its established reproductive role.
Kisspeptin Research in Men
A randomized, placebo-controlled crossover trial published in 2023 examined kisspeptin in men with HSDD, with 32 participants completing the study. Researchers administered kisspeptin-54 through an intravenous infusion and assessed brain activity, physical arousal and behavioural responses while participants viewed sexual material. Kisspeptin altered activity in sexual-processing brain networks and increased reported happiness about sex.
The study also reported an increase in penile tumescence—the swelling associated with an erection—of up to 56% more than placebo during sexual stimulation. That figure describes a measured laboratory response, rather than a 56% improvement in overall sexual performance or a treatment success rate. The findings support further research, but do not establish lasting benefits from routine use.
Kisspeptin Research in Women
A separate randomized crossover trial published in 2022 studied 32 premenopausal women with HSDD. Kisspeptin administration changed brain responses to erotic videos and facial attraction tasks, with effects in regions associated with sexual and emotional processing. These findings provide human evidence that kisspeptin can influence pathways relevant to sexual desire in women.
However, this was a short-term experimental study, rather than a trial demonstrating sustained improvements in everyday sexual satisfaction. Larger studies are needed to establish whether the observed effects translate into a practical treatment, how long benefits might last and what repeated administration would mean for safety.
Why the Form of Kisspeptin Matters
Kisspeptin exists in different forms, including kisspeptin-10 and kisspeptin-54. The sexual desire studies discussed here used kisspeptin-54 administered intravenously under controlled research conditions. Their results cannot automatically be applied to another form, another administration method or an online product simply labelled “kisspeptin.” The exact peptide and study protocol matter when interpreting a claim. The importance of delivery method is explained further in our guide to peptide bioavailability: oral vs injectable peptides.
PT-141 vs Kisspeptin: How Does the Evidence Compare?
PT-141 has the more developed clinical evidence for a defined sexual desire condition, including large phase 3 trials and a specific U.S. prescription approval. Its male erectile-function research is separate from that approved indication. Kisspeptin has encouraging controlled human findings in both sexes, but its sexual health applications remain at an earlier experimental stage.
There is no basis in these studies for declaring one peptide universally better for libido or sexual performance. They act through different signalling pathways, and the trials assessed different populations and outcomes. A meaningful comparison depends on whether the question concerns low desire, physical arousal or erectile function.
Side Effects and Research Limitations
Bremelanotide’s prescription label identifies nausea, flushing, headache, vomiting and injection-site reactions among its common adverse effects. It can temporarily increase blood pressure and reduce heart rate, and it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease. Changes in skin pigmentation and interactions affecting the absorption of oral medications are additional considerations.
For kisspeptin, the small, short-term sexual desire studies cannot establish the safety of frequent or long-term administration. Its involvement in reproductive hormone signalling also makes it important to distinguish an experimental intervention from a general wellness supplement. Promising findings warrant further clinical investigation, rather than assumptions that repeated use is harmless.
Understanding the Research Behind Sexual Health Peptides
PT-141 and kisspeptin have both been investigated in human sexual health studies, but they are at different stages of clinical development. Bremelanotide has a specific U.S. prescription approval for low sexual desire causing distress in premenopausal women; its use in men falls outside that approved indication. Kisspeptin remains investigational, with early trials exploring its effects on sexual desire and arousal in both sexes. These distinctions help readers understand what has been demonstrated and what researchers are still working to establish.
The Future of Peptides for Sexual Health
PT-141 and kisspeptin illustrate why peptide research in sexual medicine extends beyond improving blood flow. Their studies explore nervous-system signalling, reproductive pathways and how the brain responds to sexual stimuli. That creates possibilities for investigating problems that are not fully explained by erectile function alone.
The strongest conclusions remain specific: bremelanotide has demonstrated benefits for desire and associated distress in a defined group of women, while kisspeptin has produced encouraging short-term findings in men and women with low sexual desire. Further research will determine how experimental approaches translate into lasting, practical treatments. For now, understanding the evidence behind each peptide is more useful than treating “sexual performance” as a single outcome.
Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice. Research findings do not establish that every peptide product is safe or effective for personal use. Consult a qualified healthcare professional before making decisions about peptides or treatments for sexual health. For supplier information, see our guide to buying peptides in Canada.